Upadacitinib After TNF Inhibitor Failure Improves RA Control

Published Date: 30 Apr 2026

In patients with active RA, switching to upadacitinib after failure of a single TNF inhibitor is more effective in reducing disease activity at 12 weeks than using a second TNF inhibitor adalimumab.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Beyond What Is Visible in Myelofibrosis?

2.

MCh in Surgical Oncology: Admission, Medical School, Fees, Qualifications Information

3.

ASCO Future Focus: Follicular Lymphoma: Future Focus from the American Society of Clinical Onology

4.

Fake Cancer Drugs; Let's Talk About Sex; Reducing Cancer-Related Fatigue

5.

In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot